Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure [11]

Nephrology Dialysis Transplantation

Volumn 21, Issue 12, 2006, Pages 3606-3608

  Karie, Svetlana ^a   Launay Vacher, Vincent ^a   Janus, Nicolas ^a   Izzedine, Hassane ^a   Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYTOCHROME P450; ESTERASE; OSELTAMIVIR; ZANAMIVIR;

AREA UNDER THE CURVE; AVIAN INFLUENZA; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COUGHING; CREATININE CLEARANCE; DIZZINESS; DOSE CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG URINE LEVEL; EPIDEMIC; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEADACHE; HEMODIALYSIS; HUMAN; INFECTION RISK; INFLUENZA A; KIDNEY FAILURE; LETTER; MORTALITY; NONHUMAN; NOSE IRRITATION; POPULATION RISK; POPULATION SIZE; PRESCRIPTION; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROAT IRRITATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; ENZYME INHIBITORS; HUMANS; INFLUENZA, HUMAN; KIDNEY FAILURE, CHRONIC; OSELTAMIVIR; ZANAMIVIR;

EID: 33751416663     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl345     Document Type: Letter

References (8)

1. http://www.who.int/csr/disease/avian_influenza/country/ cases_table_2006_04_21/en/index.html, Accessed on the 21 April 2006.
2. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12
3. The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353: 1374-1385
4. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999; 37: 47-84
5. Izzedine H, Launay-Vacher V, Deray G. GPR Antiviraux. Guide de prescription des medicaments chez le patient insuffisant renal. Méditions International, Paris: 2003.
6. de Jong MD, Thanh TT, Khanh TH et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353: 2667-2672
7. Cass LM, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 1999; 36 [Suppl 1]: 1-11
8. Cass LM, Efthymiopoulos C, Marsh J, Bye A. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir. Clin Pharmacokinet 1999; 36 [Suppl 1]: 13-9